(Q33375423)

English

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

Ming-Sound Tsao

object named as

Ming-Sound Tsao

5

0 references

author name string

Stephen Welch

1

1 reference

Europe PubMed Central

26 July 2017

Hal W Hirte

2

1 reference

Europe PubMed Central

26 July 2017

Mark S Carey

3

1 reference

Europe PubMed Central

26 July 2017

Sebastian J Hotte

4

1 reference

Europe PubMed Central

26 July 2017

Shirley Brown

6

1 reference

Europe PubMed Central

26 July 2017

Gregory R Pond

7

1 reference

Europe PubMed Central

26 July 2017

Janet E Dancey

8

1 reference

Europe PubMed Central

26 July 2017

Amit M Oza

9

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

29 May 2007

1 reference

Europe PubMed Central

26 July 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

26 July 2017

106

1 reference

Europe PubMed Central

26 July 2017

305-310

1 reference

Europe PubMed Central

26 July 2017

2

1 reference

Europe PubMed Central

26 July 2017

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

The S-phase cytotoxicity of camptothecin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic cata

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.018

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YGYNO.2007.02.018

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33375423&oldid=1955090834"